A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Postmenopausal|Metastatic Breast Cancer
Interventions: DRUG: Tamoxifen|DRUG: Ralimetinib (LY2228820 dimesylate)
Sponsor: Centre Francois Baclesse
Collaborators: National Cancer Institute, France|ARC Foundation for Cancer Research